1\. Pathological diagnosis of epithelial ovarian cancer, 2. Presence of germline or somatic BRCA mutational status result, 3. Advanced or recurrent ovarian cancer patients who responded to their most recent platinum-based chemotherapy and plan to start PARPi (olaparib or niraparib) maintenance therapy.
You may not be if
1\. Patients who refuse to participate, 2. Patients having difficulty understanding the protocol due to language barrier
Clareo Health | Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors
